GDTC
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ: GDTC · HEALTHCARE · BIOTECHNOLOGY
$1.00
+0.71% today
Updated 2026-04-30
Market cap
$11.60M
P/E ratio
—
P/S ratio
13.47x
EPS (TTM)
$-0.27
Dividend yield
—
52W range
$1 – $4
Volume
0.0M
CytoMed Therapeutics Limited Ordinary Shares (GDTC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-471847.00 | $-692308.00 | $-1.27M | $-1.10M | $-2.59M | $-1.69M | $-3.70M |
| Capital expenditures | $872978.00 | $185289.00 | $431798.00 | $353736.00 | $44174.00 | $1.03M | $703134.00 |
| Depreciation | $132000.00 | $221486.00 | $244594.00 | $293315.00 | $288822.00 | $245558.00 | — |
| Stock-based comp | — | — | — | — | $0.00 | $0.00 | $694200.00 |
| Free cash flow | $-1.34M | $-877597.00 | $-1.70M | $-1.46M | $-2.63M | $-2.72M | $-4.40M |
| Investing cash flow | $-872978.00 | $-371943.00 | $-610724.00 | $-353370.00 | $-2.11M | $494589.00 | — |
| Financing cash flow | $887243.00 | $1.44M | $3.09M | $793255.00 | $8.16M | $-33357.00 | — |
| Dividends paid | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |